RegulatoryJun 23, 2026, 05:02 PM
NeOnc Technologies Receives UAE IND Approval for Lead Candidate NEO100
AI Summary
NeOnc Technologies Holdings, Inc. announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO100, its lead candidate. This authorization covers adult Phase 1 through Phase 2 studies and pediatric studies for progressive or recurrent Grade III or IV gliomas, expanding the company's clinical development in the UAE. NEO100 already holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations in the US, and the company anticipates reporting top-line Phase 2a data by the end of July 2026, which could support further regulatory opportunities.
Key Highlights
- DOH Abu Dhabi granted Investigational New Drug (IND) status for NEO100.
- Authorization covers NEO100-01, NEO100-02, NEO100-03 protocols for adult Phase 1, 1b, and 2 studies.
- Pediatric studies for Phase 1 and 1b also authorized, pending protocol review.
- The authorized indication is progressive or recurrent Grade III or IV gliomas.
- NEO100 holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations in the US.
- Company expects top-line Phase 2a data for NEO100-01 by end of July 2026.
- This expands NeOnc's UAE clinical development footprint, following NEO212 IND clearance.
Price Impact
More from NTHI